Novartis Secures Landmark European Approval for New Oral Skin Therapy

Basel, Monday, 27 April 2026.
Novartis secured European approval for Rhapsido, the first oral targeted therapy for chronic hives. Requiring no liver monitoring, this breakthrough safely unlocks a highly lucrative market for investors.